A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy
- 138 Downloads
The ultrarapid delayed rectifier current (IKur) carried by Kv1.5 channels, which are solely expressed in the atrium, is a potential target for safer treatment of paroxysmal atrial fibrillation (PAF). XEN-D0103 is a nanomolar ion channel blocker that selectively inhibits potassium ion flux through the Kv1.5 ion channel. The efficacy of XEN-D0103 in reducing AF burden was assessed in patients with DDDRp permanent pacemakers (PPMs) and PAF.
A double-blind, placebo-controlled, cross-over study was performed in patients with PAF and DDDRp PPMs with advanced atrial and ventricular Holters allowing beat-to-beat arrhythmia follow-up. All anti-arrhythmic drugs were withdrawn before randomised treatment. After baseline assessment, patients were randomly assigned to two treatment periods of placebo then XEN-D0103 50 mg bd, or XEN-D0103 50 mg bd then placebo.
Fifty-four patients were screened and 21 patients were eligible and included in the randomised trial. All 21 patients completed both treatment periods. The primary endpoint was change in AF burden assessed by PPM. There was no significant difference in AF burden on treatment with XEN-D0103 versus placebo. There was a reduction in the mean frequency of AF episodes (relative reduction 0.72, 95% CI 0.66 to 0.77; p < 0.0001). XEN-D0103 was safe and well tolerated, and there were no serious adverse events. XEN-D0103 did not have any apparent effect on heart rate compared to placebo.
XEN-D0103 did not reduce AF burden in patients with PAF and dual chamber pacemakers providing beat-to-beat monitoring. XEN-D0103 was well tolerated and did not have any apparent effect on heart rate. Although single-ion channel blockade with XEN-D0103 did not affect AF in this study, there might be a potential for this agent to be used in combination with other atrially specific drugs in the treatment of AF.
EudraCT trial registration number
KeywordsParoxysmal AF IKur channel blocker Dual chamber pacemakers
Compliance with ethical standards
The study protocol was reviewed and approved by the National Research Ethics Service South East Coast - Brighton and Sussex Ethics Committee. The study was conducted in compliance with International Conference on Harmonisation (ICH) good clinical practice (GCP) guidelines and all relevant local regulatory requirements and laws, and all patients gave written informed consent.
Conflict of interest
Funding support is from XENTION Limited, Cambridge, UK.
- 1.Pérula-de-Torres LÁ, et al. Opportunistic Detection of Atrial Fibrillation in Subjects Aged 65 Years or Older in Primare Care: A Randomised Clinical Trial of Efficacy. DOFA-AP Study Protocol. BMC Family Practice. 2012;13(1):106. https://doi.org/10.1186/1471-2296-13-106.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Wettwer E, Hála O, Christ T, Heubach JF, Dobrev D, Knaut M, et al. Role of IKur in controlling action potential shape and contractility in the human atrium influence of chronic atrial fibrillation. Circulation. 2004;110(16):2299–306. https://doi.org/10.1161/01.CIR.0000145155.60288.71.CrossRefPubMedGoogle Scholar
- 16.de Haan S, et al. AVE0118, blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006;114(12):1234–42. https://doi.org/10.1161/CIRCULATIONAHA.106.630905.CrossRefPubMedGoogle Scholar
- 17.Christ T, Wettwer E, Voigt N, Hála O, Radicke S, Matschke K, et al. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol. 2008;154(8):1619–30. https://doi.org/10.1038/bjp.2008.209.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011;4(5):637–43. https://doi.org/10.1161/CIRCEP.111.962340.CrossRefPubMedGoogle Scholar